Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir Dose-Ranging Study for Resistant/Refractory CMV in Transplant Recipients
NCT01611974Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of maribavir in cytomegalovirus infection (CMV) (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 Weeks and Number of Participants With a Treatment Emergent Adverse Event (TEAE) at 25 weeks. Started Jul 2012; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01611974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611974.